GlassScriptPhysician profile
Justin V Chandler
NPI 1750657599
$124,031.74
in general payments reported to CMS, 2019-2025
17 companies · $74K in 2025
The $74K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.47 · 2021: $14K · 2022: $241 · 2023: $64.30 · 2024: $36K · 2025: $74K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Honoraria: $42K · Travel and Lodging: $9,569 · Consulting Fee: $8,298 · Food and Beverage: $2,830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $47,006.25 |
| Honoraria | $41,800.00 |
| Travel and Lodging | $9,569.38 |
| Consulting Fee | $8,297.50 |
| Food and Beverage | $2,830.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $62,086.86 | 2024-2025 | |
| Axsome Therapeutics, INC. | $47,188.89 | 2025 | Symbravo |
| Astrazeneca Pharmaceuticals LP | $13,938.82 | 2021-2022 | |
| Abbvie INC. | $312.56 | 2021-2024 | |
| Lilly USA, LLC | $159.83 | 2021-2025 | Kisunla |
| Teva Pharmaceuticals USA, INC. | $79.58 | 2021-2023 | Austedo |
| Amgen INC. | $49.95 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $47.74 | 2021-2023 | Xywav |
| Kyowa Kirin, INC. | $34.90 | 2022 | |
| Sk Life Science, INC. | $26.11 | 2021 | |
| Ucb, INC. | $23.88 | 2022 | |
| Impel Pharmaceuticals INC. | $16.57 | 2023 | Trudhesa |
| Sunovion Pharmaceuticals INC. | $14.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Acadia Pharmaceuticals INC | $13.41 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $11.80 | 2022 | |
| Novartis Pharmaceuticals Corporation | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.